Regeneron Pharmaceuticals, Inc. REGN

NAS: REGN | ISIN: US75886F1075   22/09/2023
824,84 USD (+0,18%)
(+0,18%)   22/09/2023
Grafiek Regeneron Pharmaceuticals, Inc. Grafiek Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. in het nieuws

19 mei 2023 · High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023 · Persbericht

15 maart 2023 · Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease · Persbericht

24 januari 2023 · Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition · Persbericht

23 december 2022 · Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer · Persbericht

21 december 2022 · Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine · Persbericht

19 december 2022 · Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference · Persbericht

16 december 2022 · Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis · Persbericht

15 december 2022 · Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis · Persbericht

12 december 2022 · Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial · Persbericht

12 december 2022 · Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma · Persbericht

Profiel Regeneron Pharmaceuticals, Inc.

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.regeneron.com

Hoofdzetel: Tarrytown, New York vlag Verenigde Staten

CEO: Leonard Schleifer

Werknemers: 12.748

Aandelen Regeneron Pharmaceuticals, Inc.

Beurswaarde: 87,89 miljard USD

Effecten: 106,74 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,51

Mijn selecties